As studies in other cancer types already showed that survivin can also be measured in the serum [31–35], our aim was to evaluate whether serum survivin levels influence the outcome of cisplatin-based chemotherapy in patients with malignant mesothelioma. This evidence concerns the gene BIRC5 and malignant mesothelioma.